JP Morgan Chase’s Quest Diagnostics DGX Stock Holding History

JP Morgan Chase’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,000	Closed	-$3.42M	–	7456
2024 Q2	$3.42M	Buy	+25,000	New	+$3.42M	﹤0.01%	3337
2020 Q2	–	Sell	-129,600	Closed	-$10.4M	–	5430
2020 Q1	$10.4M	Buy	+129,600	New	+$13.4M	﹤0.01%	1708
2019 Q2	–	Sell	-100,800	Closed	-$9.06M	–	5799
2019 Q1	$9.06M	Buy	+100,800	New	+$8.73M	﹤0.01%	2134
2016 Q1	–	Sell	-1,100	Closed	-$78K	–	4712
2015 Q4	$78K	Buy	+1,100	New	+$74K	﹤0.01%	3827

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase's DGX Position: Q1 2026 in Review

JP Morgan Chase reduced its Quest Diagnostics (DGX) stake by 7.2% in Q1 2026, selling an estimated $58.2M and leaving 3,846,456 shares worth $758M. The position accounts for 0.05% of the portfolio, ranked #317.

JP Morgan Chase first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $823M in Q3 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

JP Morgan Chase held 3,846,456 shares of Quest Diagnostics worth $758M as of Q1 2026.
JP Morgan Chase sold 299,440 Quest Diagnostics shares in Q1 2026, an estimated $58.2M.
Quest Diagnostics made up 0.05% of JP Morgan Chase's portfolio in Q1 2026, its #317 holding.
JP Morgan Chase first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Quest Diagnostics position peaked at $823M in Q3 2025.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.